Merck and Cubist Pharmaceuticals have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist’s average stock price for the most recent five trading days. Read the full story

Pfizer and Merck & Co announced a clinical trial biotech partnering deal to test Merck’s Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer’s Crizotinib (XALKORI) in combination for patients with ALK-positive advanced or metastatic non-small cell lung cancer. Read the full story

Merck and Ferring Pharmaceuticals announced their  pharma partnership with the World Health Organization to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding (post-partum hemorrhage) in women after childbirth, that is designed to be stable at room temperature, even in hot and tropical climates. Read the full story

Merck enters into a pharma licensing deal with GSK for evaluating combination therapy for renal cell carcinoma. Read the full story

Forest Laboratories, big pharma, announced that is acquiring exclusive rights in the United States for Saphris (asenapine). Read the full story

Merck & Co considering a break off of their animal-health and consumer product division, which could boost their share hold value by $50 billion. Read the full story

Polyplus-transfection and Merck & Co, announced a global prior use Pharma licensing deals agreement and extended supply agreement for Polyplus-transfection’s polyethylenimine based transfection reagents. Read the full story